Q2 EPS Estimate for Context Therapeutics Lowered by Analyst

Context Therapeutics Inc. (NASDAQ:CNTX) – HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for shares of Context Therapeutics in a research note issued to investors on Thursday, May 8th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.05) per share for the quarter, down from their prior forecast of ($0.04). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.44) EPS, FY2028 earnings at ($0.48) EPS and FY2029 earnings at ($0.32) EPS.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05).

A number of other analysts have also recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Context Therapeutics in a research report on Tuesday, April 29th. D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Thursday, May 8th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $5.40.

Context Therapeutics Stock Down 0.1%

Shares of NASDAQ CNTX opened at $0.78 on Monday. The stock has a market cap of $69.96 million, a PE ratio of -0.86 and a beta of 2.11. Context Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.75. The business has a 50-day moving average price of $0.78 and a 200 day moving average price of $1.10.

Institutional Trading of Context Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CNTX. Jane Street Group LLC acquired a new stake in Context Therapeutics during the 4th quarter worth approximately $29,000. Citadel Advisors LLC purchased a new position in shares of Context Therapeutics during the 4th quarter worth approximately $31,000. Shay Capital LLC purchased a new position in shares of Context Therapeutics during the 4th quarter worth approximately $52,000. Clear Harbor Asset Management LLC raised its stake in shares of Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after buying an additional 21,804 shares in the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Context Therapeutics during the 4th quarter worth approximately $94,000. 14.03% of the stock is owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.